AIM
ACRS icon

Alambic Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

Alambic Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-59,766
Closed -$154K – 2
2020
Q3 		$154K Sell
59,766
-30,920
-34% -$69.2K 1.69% 21
2020
Q2 		$147K Sell
90,686
-7,600
-8% -$10.2K 0.37% 112
2020
Q1 		$102K Sell
98,286
-16,750
-15% -$22.8K 0.25% 130
2019
Q4 		$217K Sell
115,036
-35,600
-24% -$59K 0.18% 202
2019
Q3 		$163K Buy
150,636
+97,936
+186% +$139K 0.12% 230
2019
Q2 		$115K Buy
+52,700
New +$287K 0.07% 264

Other funds holding ACRS

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alambic Investment Management's ACRS Position: Q4 2020 in Review

Alambic Investment Management sold out of Aclaris Therapeutics (ACRS) in Q4 2020, closing a stake of 59,766 shares — an estimated $154K sold.

Alambic Investment Management first reported a position in ACRS in Q2 2019 and held it in 6 quarters. The position peaked at $217K in Q4 2019. 82 funds tracked by Wall St. Rank hold ACRS as of Q4 2020.

  • Alambic Investment Management reported no remaining Aclaris Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Alambic Investment Management sold 59,766 Aclaris Therapeutics shares in Q4 2020, an estimated $154K.
  • Alambic Investment Management first reported a position in Aclaris Therapeutics in Q2 2019 and held it in 6 quarters.
  • Alambic Investment Management's Aclaris Therapeutics position peaked at $217K in Q4 2019.
  • 82 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.